## Cervical Fusion Post-Op [1819]

General	
Common Present on Admission Diagnosis	
[] Acidosis	Post-op
[] Acute Post-Hemorrhagic Anemia	Post-op
[] Acute Renal Failure	Post-op
[] Acute Respiratory Failure	Post-op
[] Acute Thromboembolism of Deep Veins of Lower Extremities	Post-op
[] Anemia	Post-op
[] Bacteremia	Post-op
Bipolar disorder, unspecified	Post-op
[] Cardiac Arrest	Post-op
[] Cardiac Dysrhythmia	Post-op
[] Cardiogenic Shock	Post-op
Decubitus Ulcer	Post-op
Dementia in Conditions Classified Elsewhere	Post-op
Disorder of Liver	Post-op
[] Electrolyte and Fluid Disorder	Post-op
[] Intestinal Infection due to Clostridium Difficile	Post-op
Methicillin Resistant Staphylococcus Aureus Infection     Obstructive Chronic Bronchitis with Exacerbation	Post-op
	Post-op
	Post-op
Other and Unspecified Coagulation Defects     Other Pulmonary Embolism and Infarction	Post-op Post-op
Other Full Indianal Embolish and Inflatction     Phlebitis and Thrombophlebitis	Post-op
Protein-calorie Malnutrition	Post-op
Psychosis, unspecified psychosis type	Post-op
Schizophrenia Disorder	Post-op
Sepsis	Post-op
Septic Shock	Post-op
Septicemia	Post-op
[] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Post-op
Urinary Tract Infection, Site Not Specified	Post-op
Elective Outpatient, Observation, or Admission (Single	Response)
( ) Elective outpatient procedure: Discharge following routine recovery	Routine, Continuous, PACU & Post-op
( ) Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
	Bed request comments:
/ \ Outration time that a set of a set	PACU & Post-op
() Outpatient in a bed - extended recovery	Diagnosis: Admitting Physician:
	Bed request comments:
	PACU & Post-op
( ) Admit to Inpatient	Diagnosis:
( )	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights. PACU & Post-op
Printed on 9/17/2020 at 8:35 AM from SUP	Page 1 of 2

Admission	or Observation	(Single	Respo	nse)
Patient ha	as active outpati	ent statu	s order	on file

( ) Admit to Inpatient	Diagnosis: Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgmen
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	PACU & Post-op
) Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
·	Patient Condition:
	Bed request comments:
	PACU & Post-op
Outpatient in a bed - extended recovery	Diagnosis:
	Admitting Physician:
	Bed request comments:
	PACU & Post-op
) Transfer patient	Level of Care:
	Bed request comments:
	Scheduling/ADT
) Return to previous bed	Routine, Until discontinued, Starting S, Scheduling/ADT
Admission (Single Response) Patient has active status order on file	
( ) Admit to inpatient	Diagnosis:
	Admitting Physician:
•	Admitting Physician: Level of Care:
	Admitting Physician: Level of Care: Patient Condition:
	Admitting Physician: Level of Care: Patient Condition: Bed request comments:
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care:
	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments:
) Transfer patient	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT
( ) Transfer patient	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments:
( ) Transfer patient	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT
( ) Transfer patient  ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT
( ) Transfer patient  ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care:
( ) Transfer patient ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Level of Care: Bed request comments:
( ) Transfer patient ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file ( ) Transfer patient	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care:
( ) Transfer patient  ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file  ( ) Transfer patient  ( ) Return to previous bed	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Level of Care: Bed request comments: Scheduling/ADT
( ) Transfer patient ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file ( ) Transfer patient ( ) Return to previous bed  Code Status	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Routine, Until discontinued, Starting S, Scheduling/ADT
( ) Transfer patient  ( ) Return to previous bed  Transfer (Single Response) Patient has active inpatient status order on file  ( ) Transfer patient  ( ) Return to previous bed	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Code Status decision reached by:
<ul> <li>) Transfer patient</li> <li>) Return to previous bed</li> <li>Fransfer (Single Response) Patient has active inpatient status order on file</li> <li>) Transfer patient</li> <li>) Return to previous bed</li> <li>Code Status</li> <li>] Full code</li> </ul>	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Routine, Until discontinued, Starting S, Scheduling/ADT
Transfer patient  Return to previous bed  Fransfer (Single Response) Patient has active inpatient status order on file  Transfer patient  Return to previous bed  Code Status	Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT  Code Status decision reached by:

[] Consult to Palliative Care Service	Priority: Reason for Consult? Order? Name of referring provider: Enter call back number:
[] Consult to Social Work	Reason for Consult: Post-op
[] Modified Code	Does patient have decision-making capacity?  Modified Code restrictions:  Post-op
[] Treatment Restrictions	Treatment Restriction decision reached by: Specify Treatment Restrictions: Post-op
Isolation	
[ ] Airborne isolation status	
[] Airborne isolation status	Details
[] Mycobacterium tuberculosis by PCR - If you suspect Tuberculosis, please order this test for rapid diagnostics.	Once, Sputum, Post-op
[] Contact isolation status	Details
[] Droplet isolation status	Details
[] Enteric isolation status	Details
Precautions	
[] Aspiration precautions	PACU & Post-op
[X] Fall precautions	Increased observation level needed: PACU & Post-op
[] Latex precautions	PACU & Post-op
[] Seizure precautions	Increased observation level needed: PACU & Post-op
[] Spinal precautions	PACU & Post-op
Nursing	
Vital Signs (Single Response)	
(X) Vital signs - T/P/R/BP	Routine, Per unit protocol, PACU & Post-op
Activity	
[] Strict bed rest	Routine, Until discontinued, Starting S, PACU & Post-op
[] Up with assistance	Routine, Until discontinued, Starting S Specify: Up with assistance PACU & Post-op
[] Activity as tolerated	Routine, Until discontinued, Starting S Specify: Activity as tolerated PACU & Post-op
[] Ambulate with assistance	Routine, Every 8 hours Specify: with assistance,in hall Ambulate with assistance at least 3 times a day, ambulate in hallway by tomorrow AM., PACU & Post-op
[] Up in chair for all meals	Routine, Until discontinued, Starting S Specify: Up in chair Additional modifier: for meals All meals, PACU & Post-op
[] Elevate Head of bed 30 degrees	Routine, Until discontinued, Starting S Head of bed: 30 degrees PACU & Post-op
[] Head of bed flat	Routine, Until discontinued, Starting S Head of bed: flat PACU & Post-op

[X] Assess for neck swelling and airway compromise	Routine, Every 4 hours For 24 Hours Assess: for neck swelling and airway compromise PACU & Post-op
[X] Straight cath	Routine, Every 6 hours If unable to void after second attempt, insert Foley and call physician., PACU & Post-op
[X] Insert/Maintain Foley and Notify	
[X] Insert Foley catheter	Routine, Once Type: Size: Urinometer needed: If unable to void after second attempt at straight cath, insert Foley and caphysician, PACU & Post-op
[X] Foley catheter care	Routine, Until discontinued, Starting S Orders: Maintain to gravity/bedside drain, PACU & Post-op
[X] Notify Physician if unable to void after second attempt at straight cath and Foley inserted	Routine, Until discontinued, Starting S, PACU & Post-op
[] Surgical/incision site care	Routine, Once Location: Site: Apply: Dressing Type: Open to air? PACU & Post-op
[] Reinforce dressing	Routine, As needed Reinforce with: If saturated., PACU & Post-op
[] Cervical collar - soft	Routine, Once Type of Collar to Apply: Soft cervical collar Special Instructions: obtain from central supply PACU & Post-op
[] Cervical collar - Philadelphia	Routine, Once Type of Collar to Apply: Philadelphia Collar Special Instructions: Obtain from central supply. PACU & Post-op
[] Cervical collar - Miami J	Routine, Once Type of Collar to Apply: Miami J Collar Special Instructions: Obtain from orthotic provider. PACU & Post-op
[] Call Raborn Orthotics at 713-349-8117 for applica orthotic device	
[] Drain care	Routine, Until discontinued, Starting S Drain 1: Drain 2: Drain 3: Drain 4: All Drains: PACU & Post-op
[] Place antiembolic stockings - Bilateral thigh high	Routine, Once May remove once patient ambulatory, PACU & Post-op
[] No anticoagulants INcluding UNfractionated hepar	
[] No anti-platelet agents INcluding aspirin	Routine, Until discontinued, Starting S Reason for "No" order: PACU & Post-op

[X] Notify Physician of neck swelling or if airway compromised	Routine, Until discontinued, Starting S, PACU & Post-op
[X] Notify Physician if acute change in neurological status	Routine, Until discontinued, Starting S, PACU & Post-op
[X] Notify Physician bleeding at site	Routine, Until discontinued, Starting S, PACU & Post-op
[X] Notify Physician of No Bowel Movement for more than 72 hours	Routine, Until discontinued, Starting S, PACU & Post-op
Diet	
Diet - Clear liquids (advance as tolerated to Regular)	Diet effective now, Starting S Diet(s): Clear Liquids Advance Diet as Tolerated? Yes Target Diet: Regular Advance target diet criteria: Please assess bowel sounds between progressions. Liquid Consistency: Fluid Restriction: Foods to Avoid: PACU & Post-op
[] Diet - Full liquids	Diet effective now, Starting S Diet(s): Full Liquids Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: PACU & Post-op
[] Diet - Regular	Diet effective now, Starting S Diet(s): Regular Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: PACU & Post-op
[] Diet - Heart healthy	Diet effective now, Starting S Diet(s): Heart Healthy Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: PACU & Post-op
[] Diet - 2000 Kcal/255 gm Carb	Diet effective now, Starting S Diet(s): 2000 Kcal/225 gm Carbohydrate Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: PACU & Post-op
[] Diet	Diet effective now, Starting S Diet(s): Other Options: Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: PACU & Post-op
Education	
[] Patient education - Activity	Routine, Once Patient/Family: Education for: Activity PACU & Post-op

[X] Patient education - Deep breathing and coughing	Routine, Once
exercises	Patient/Family:
	Education for: Other (specify) Specify: Deep breathing and coughing exercises
	PACU & Post-op
[X] Patient education - Incentive spirometry	Routine, Once
	Patient/Family:
	Education for: Incentive spirometry
	PACU & Post-op
[X] Patient education - Pain management	Routine, Once
	Patient/Family:
	Education for: Other (specify)
	Specify: Pain management PACU & Post-op
Patient education - Smoking cessation	Routine, Once
[] I alient education - emoking eessation	Patient/Family:
	Education for: Smoking cessation counseling
	PACU & Post-op
[X] Patient education - Wound care	Routine, Once
	Patient/Family:
	Education for: Other (specify)
	Specify: Wound care
	PACU & Post-op
IV Fluids	
IV Fluids (Single Response)	
( ) lactated Ringer's infusion	intravenous, continuous, Post-op
() sodium chloride 0.9 % infusion	intravenous, continuous, Post-op
() sodium chloride 0.9 % with potassium chloride 20	mEq/L intravenous, continuous, Post-op
infusion	
() dextrose 5 % and sodium chloride 0.45 % with	intravenous, continuous, Post-op
potassium chloride 20 mEq/L infusion - for NPO Pa	alients
Medications	
Steroids (Single Response)	
( ) dexamethasone (DECADRON) IV	4 mg, intravenous, every 6 hours scheduled, Post-op
() methylPREDNISolone sodium succinate	40 mg, intravenous, every 6 hours scheduled, Post-op
(Solu-MEDROL) injection	
() methylPREDNISolone (MEDROL PAK) dose pack	(start
in AM)	
THIS A PANEL. DO NOT EDIT.	
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, before breakfast - one time, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, after lunch - one time, S at 12:00 PM, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, after dinner - one time, For 1 Doses, Post-op
[] meanym rezervesions (mzzrecz) taziet	All day-1 doses may be given (up to 6 tablets) may be given at one time based on time of day.
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, nightly - one time, For 1 Doses, Post-op
	All day-1 doses may be given (up to 6 tablets) may be given at one time
	based on time of day.
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, 3 times daily around food, Starting S+1, For 3 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, nightly - one time, Starting S+1, For 1 Doses, Post-op
[1] mothy/DDEDNISolone (MEDDOL) toblet	A mg. aral. A times deily tenering. Starting C. 2. Deet on

## **NSAIDS (Single Response)**

These orders should be used for Cervical Arthroplasty. Use in spinal fusion patients is not recommended.

4 mg, oral, 4 times daily tapering, Starting S+2, Post-op

[] methylPREDNISolone (MEDROL) tablet

( ) indomethacin (INDOCIN) capsule	50 mg, oral, 3 times daily with meals, Starting S+1, Post-op Start POD #1. Use in spinal fusion patients not
	recommended.
( ) indomethacin SR (INDOCIN SR) CR capsule	75 mg, oral, daily with breakfast, Starting S+1, Post-op Start POD #1. Use in spinal fusion patients not recommended.
Medications	
pantoprazole (PROTONIX) IV or ORAL	"Or" Linked Panel
[] pantoprazole (PROTONIX) EC tablet	40 mg, oral, daily at 0600, Post-op
[] participazote (Free Fortix) Eo tablet	Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection	40 mg, intravenous, daily at 0600, Post-op Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
Medications - Bowel Management	
] polyethylene glycol (MIRALAX) packet	17 g, oral, 2 times daily, Post-op
Stool Softener Options (Single Response)	
( ) docusate sodium (COLACE) capsule	100 mg, oral, 2 times daily, Post-op
() sennosides-docusate sodium	2 tablet, oral, nightly, Post-op
(SENOKOT-S) 8.6-50 mg per tablet	
Antibiotics - NOT HMWB (Single Response)	
) Antibiotics - Neurosurgery - patients with surgical drains	
[] cefazolin (ANCEF) IV - until drains removed	1 g, intravenous, every 8 hours, Post-op
	Administer until all drains removed.
	Type of Therapy: New Anti-Infective Order
[] cefepime (MAXIPIME) IV - until drains	Reason for Therapy: Surgical Prophylaxis  1 g, intravenous, every 12 hours, Post-op
[] cefepime (MAXIPIME) IV - until drains removed	Administer until all drains removed.
Temoved	Type of Therapy: New Anti-Infective Order
	Reason for Therapy: Surgical Prophylaxis
[] vancomycin (VANCOCIN) - until drains	1 g, intravenous, every 12 hours, Post-op
removed	Administer until all drains removed.
	Type of Therapy: New Anti-Infective Order
	Reason for Therapy: Surgical Prophylaxis
NACTION N	Indication:
<ul> <li>Antibiotics - Neurosurgery - patients withOUT sur site drains</li> </ul>	rgical
[] cefazolin (ANCEF) IV	1 g, intravenous, once, Starting H, For 1 Doses, Post-op
	Type of Therapy: New Anti-Infective Order
	Reason for Therapy: Surgical Prophylaxis
[] cefepime (MAXIPIME) IV	1 g, intravenous, once, Starting H, For 1 Doses, Post-op
	Type of Therapy: New Anti-Infective Order
I I vancomycin (\/ANCOCINI\	Reason for Therapy: Surgical Prophylaxis
[] vancomycin (VANCOCIN)	1 g, intravenous, once, Starting H, For 1 Doses, Post-op
	Type of Therapy: New Anti-Infective Order Reason for Therapy: Surgical Prophylaxis
	Indication:
<b>N</b> edications	
] benzocaine-menthol (CEPACOL MAX) lozenge 1	5-3.6 1 lozenge, buccal, PRN, sore throat, Post-op
mg  hope 1.4.9/ (CHLOBASEDTIC) enroy for notice	onto who 2 onrow Mouth/Throat over 2 have DDN same thing the
] phenol 1.4 % (CHLORASEPTIC) spray - for patie cannot tolerate lozenges	ents who 2 spray, Mouth/Throat, every 3 hours PRN, sore throat, Post-op
Muscle Relaxants (Single Response)	
) methocarbamol (ROBAXIN) 500 mg in sodium ch	
0.9 % 100 mL IVPB	muscle spasms, Post-op

( ) cyclobenzaprine (FLEXERIL) tablet	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op
Muscle Relaxants - Refractory Treatments (Single	e Response)
( ) diazepam (VALIUM) injection	2.5 mg, intravenous, every 8 hours PRN, muscle spasms, inadequate muscle spasm relief following administration of other agents, Post-op Indication(s): Other Specify: Muscle Relaxant
( ) diazepam (VALIUM) tablet	2.5 mg, oral, every 8 hours PRN, muscle spasms, inadequate muscle spasm relief following administration of other agents, Post-op Indication(s): Other Specify: Muscle Relaxant
Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral (Selection Red	quired) "Or" Linked Panel
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset or action is required.
[] promethazine (PHENERGAN) IV or Oral or Recta	al "Or" Linked Panel
[] promethazine (PHENERGAN) 12.5 mg IV	12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
<ul><li>[] scopolamine (TRANSDERM-SCOP) 1.5 mg (1 m days) - For Patients LESS than 65 years old</li><li>PRN Medications - Symptom Management</li></ul>	g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op
[] acetaminophen (TYLENOL) tablet	650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op
[] Itching - Neurosurgery medications (Single Response	
Avoid diphenhydramine use in patients over 70 y	ears old when possible.
() cetirizine (ZyrTEC) tablet	5 mg, oral, daily PRN, itching, Post-op
( ) diphenhydrAMINE (BENADRYL) injection	12.5 mg, intravenous, every 12 hours PRN, itching, Post-op
PRN Medications - Bowel Management (Single Re	esponse)
() magnesium hydroxide suspension	30 mL, oral, daily PRN, constipation, Post-op
( ) bisacodyl (DULCOLAX) EC tablet	5 mg, oral, daily PRN, constipation, Post-op
( ) bisacodyl (DULCOLAX) suppository	10 mg, rectal, daily PRN, constipation, Post-op
( ) magnesium citrate solution	150 mL, oral, daily PRN, constipation, For 2 Doses, Post-op
PRN Medications - Bowel Management	
[] saline,mineral oil,glycerin (S.M.O.G.) enema	180 mL, rectal, once, Post-op
PRN Medications - Pain - Pain Score (1-3) (Single	
( ) traMADol (ULTRAM) tablet	25 mg, oral, every 4 hours PRN, mild pain (score 1-3), Post-op Maximum Daily Dose: 200 mg/day
PCA Medications (Single Response)	
() morPHINE PCA 30 mg/30 mL	

[]	morPHINE 30 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 1 mg Lockout Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.
	Vital signs - T/P/R/BP	Routine, Per unit protocol  - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then  - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then  - Every 4 hours until PCA therapy is discontinued.  - Immediately following PCA administration tubing change, Post-op
	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
() <u>h</u> []	hydromorPHONE PCA (DILAUDID) 15 mg/30 mL hydromorPHONE (DILAUDID) 15 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 0.2 mg Lockout: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg every {Bolus Frequency:26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:

	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
( ) fe	entaNYL PCA (SUBLIMAZE) 1500 mcg/30 mL	
	fentaNYL (SUBLIMAZE) 1500 mcg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 10 mcg Lockout (recommended 6-8 min): Not Ordered Continuous Dose: 0 mcg/hr MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op **Due to fentaNYL 600 mcg/30 mL shortages, the new standard for all facilities will be fentaNYL 1500 mcg/30 mL. This concentration is 2.5 x more concentrated.**
		Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
	Vital signs - T/P/R/BP	Routine, Per unit protocol  - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then  - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then  - Every 4 hours until PCA therapy is discontinued.  - Immediately following PCA administration tubing change, Post-op

[] Richmond agita	ation sedation scale	Routine, Once Hold infusion daily at: Target RASS:
		BIS Monitoring (Target BIS: 40-60):
		60 minutes after administration of pain medication AND every 4 hours.
		Assess and document side effects of at least every 4 hours for duration of
		therapy and when patient complains of pain and/or side effects., Post-op
[] Notify Physician	n (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued
	· · · · · · · · · · · · · · · · · · ·	for any reason
		- Inadequate analgesia
		- Prior to administration of any other narcotics, antiemetics, or sedatives
		other than those ordered by the prescriber responsible for IV PCA therapy
		<ul> <li>PCA pump discontinued by any service other than the prescriber</li> </ul>
		responsible for IV PCA therapy, Post-op
	oump and call ordering	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or
	or CERT team for any of the	less
following:		- Severe and/or recent confusion or disorientation
		- POSS sedation level 4: Somnolent and difficult to arouse
		- Sustained hypotension (SBP less than 90)
		- Excessive nausea or vomiting
[] nelevene (NAD	CAND O 4 mag/mol inication	- Urinary retention, Post-op
[] naloxone (NAR 0.2 mg	CAN) 0.4 mg/mL injection	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to
0.2 mg		arouse (POSS GREATER than 3)., Post-op
		Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4
		mg). If naloxone is needed, please call the ordering physician and/or
		CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15
		minutes for 3 times.
PCA Medications (Si	ingle Response)	
PCA Medications (Si () morPHINE PCA 3	0 mg/30 mL	Loading Dose (optional): Not Ordered PCA Dose: 1 mg Lockout
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists,
() morPHINE PCA 3	0 mg/30 mL	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE.
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then
() morPHINE PCA 3	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus
() morPHINE PCA 3 [] morPHINE 30 n	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued.
() morPHINE PCA 3 [] morPHINE 30 n	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
() morPHINE PCA 3 [] morPHINE 30 n	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op Routine, Once
() morPHINE PCA 3 [] morPHINE 30 n	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60):
() morPHINE PCA 3 [] morPHINE 30 n	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours.
() morPHINE PCA 3 [] morPHINE 30 n	0 mg/30 mL mg/30 mL PCA	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60):

[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason
		- Inadequate analgesia
		- Prior to administration of any other narcotics, antiemetics, or sedatives
		other than those ordered by the prescriber responsible for IV PCA therapy
		- PCA pump discontinued by any service other than the prescriber
		responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or
.,	physician and/or CERT team for any of the	less
	following:	- Severe and/or recent confusion or disorientation
	ionownig.	- POSS sedation level 4: Somnolent and difficult to arouse
		- Sustained hypotension (SBP less than 90)
		- Excessive nausea or vomiting
		- Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection	0.2 mg, intravenous, once PRN, respiratory depression, as needed for
	0.2 mg	respiratory rate 8 per minute or less OR patient somnolent and difficult to
	-	arouse (POSS GREATER than 3)., Post-op
		Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4
		mg). If naloxone is needed, please call the ordering physician and/or
		CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15
		minutes for 3 times.
\ <b>b</b> .	udramarDLIONE DOA (DILALIDID) 45 mar/20 ml	
	ydromorPHONE PCA (DILAUDID) 15 mg/30 mL	
[]	hydromorPHONE (DILAUDID) 15 mg/30 mL	Loading Dose (optional): Not Ordered PCA Dose: 0.2
	PCA	mg Lockout: Not Ordered Continuous Dose: 0 mg/hr MAX
		(Four hour dose limit): 3 mg
		intravenous, continuous, Post-op
		Management of breakthrough pain. Administer only if respiratory rate 12
		per minute or more and POSS level of 2 or less. If more than 2 bolus
		doses in 12 hours or if pain persists after increase in demand dose, call
		ordering prescriber. For breakthrough pain in patients ages 19-59 years
		old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg
		every {Bolus Frequency:26663::"3"} hours as needed. If pain persists,
		may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE.
		Adjust doses for age, renal function or other factors.
		Turn Off PCA Continuous Dose (Basal Rate) On Date:
		Turn Off PCA Continuous Dose (Basal Rate) At Time:
[]	Vital signs - T/P/R/BP	Routine, Per unit protocol
		- Initially and every 30 minutes for 1 hour after PCA started, bolus
		administration or dose change; then
		- Every hour x 2 starting second hour after PCA started, bolus
		administered or dose change; then
		- Every 4 hours until PCA therapy is discontinued.
		- Immediately following PCA administration tubing change, Post-op
IJ	Richmond agitation sedation scale	Routine, Once
		Hold infusion daily at:
		Target RASS:
		BIS Monitoring (Target BIS: 40-60):
		60 minutes after administration of pain medication AND every 4 hours.
		Assess and document side effects of at least every 4 hours for duration of
		therapy and when patient complains of pain and/or side effects., Post-op
<u> </u>	Notify Physician (Specify)	· · · · · · · · · · · · · · · · · · ·
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued
		for any reason
		- Inadequate analgesia
		- Prior to administration of any other narcotics, antiemetics, or sedatives
		other than those ordered by the prescriber responsible for IV PCA therapy
		- PCA pump discontinued by any service other than the prescriber
		responsible for IV PCA therapy, Post-op
		127

	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
() f	entaNYL PCA (SUBLIMAZE) 600 mcg/30 mL	
	fentaNYL (SUBLIMAZE) 600 mcg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 10 mcg Lockout Interval: Not Ordered Continuous Dose: 0 mcg/hr MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors.  Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op

arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
Response)
g per 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Do not exceed 3000 mg of acetaminophen daily from all sources.
50 mg, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Maximum Daily Dose: 200 mg/day
Response)
g per  2 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op Do not exceed 3000 mg of acetaminophen daily from all sources.
25 mcg, intravenous, every 2 hour PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relie
2 mg, intravenous, every 3 hours PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relie
0.5 mg, intravenous, every 3 hours PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relie
(Selection Required) URL: "\appt1.pdf"
Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
etors
Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgate early ambulation

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate risk of VTE	Routine, Once, PACU & Post-op
<ul> <li>Moderate Risk Pharmacological Prophylaxis - Patient (Single Response) (Selection Required</li> </ul>	
( ) Contraindications exist for pharmacologic pro BUT order Sequential compression device	
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
Contraindications exist for pharmacologic pro AND mechanical prophylaxis	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once  No pharmacologic VTE prophylaxis due to the following contraindication(s):  PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once  No mechanical VTE prophylaxis due to the following  contraindication(s):  PACU & Post-op
( ) enoxaparin (LOVENOX) injection (Single Res (Selection Required)	sponse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
( ) patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
( ) patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
<ul><li>( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li></ul>	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU 8 Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS
ed on 9/17/2020 at 8:35 AM from SLIP	than 50kg and age GREATER than 75yrs.

		( ) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
l		() Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
l		(COUMADIN)	Indication:
	()	MODERATE Risk of DVT - Non-Surgical (Selection	
П		B : '	

Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once, PACU & Post-op
<ul> <li>[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selec Required)</li> </ul>	
<ul> <li>( ) Contraindications exist for pharmacologic proportion</li> <li>Order Sequential compression device</li> </ul>	phylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
Contraindications exist for pharmacologic propagation AND mechanical prophylaxis	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[ ] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
( ) patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
( ) patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):

()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
()	heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op
	for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LESS
	weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op
	,	Indication:
$\overline{()}$	Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
,	(COUMADIN)	Indication:

() HIGH Risk of DVT - Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
] High Risk Pharmacological Prophylaxis - Surgi (Single Response) (Selection Required)	cal Patient
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() (0) (5) (0) (1) (2)	PACU & Post-op
( ) enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30
() (; ) : 11.4401 OPEATED AND	mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1
CICI GREATER than 30 ML/Milli	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op
( ) Torradparinax ( ) it in the try injudicin	If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced
	Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU &
for patients with high risk of bleeding, e.g.	Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

<sup>[]</sup> Mechanical Prophylaxis (Single Response) (Selection Required)

	( ) Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
$\overline{}$	111011 D. 1 (D) (T ) 1 (O ) 1 (O ) 1	

() HIGH Risk of DVT - Non-Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High risk of VTE	Routine, Once, PACU & Post-op
<ul> <li>High Risk Pharmacological Prophylaxis - Non-Sin Patient (Single Response) (Selection Required)</li> </ul>	urgical
( ) Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
	PACU & Post-op
<ul><li>( ) enoxaparin (LOVENOX) injection (Single Resp (Selection Required)</li></ul>	onse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S
	For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND	30 mg, subcutaneous, 2 times daily, Starting S
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 3
	mL/min
() patients weight 140 kg or GREATER AND	40 mg, subcutaneous, 2 times daily, Starting S
CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 3
	mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medicati
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced
	Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
( ) heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours
for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LES
weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700
	Indication:
( ) Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
(COUMADIN)	Indication:
Mechanical Prophylaxis (Single Response) (Sele	ection
Required)	
( ) Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s
1 1 3	PACU & Post-op
( ) Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous	,,

Required)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required) [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis  () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin () enoxaparin (LOVENOX) syringe () enoxaparin () e	
High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required)   Contraindications exist for pharmacologic prophylaxis	
(Arthroplasty) Surgical Patient (Single Response) (Selection Required)  () Contraindications exist for pharmacologic prophylaxis	
( ) Contraindications exist for pharmacologic prophylaxis  ( ) apixaban (ELIQUIS) tablet  ( ) aspirin chewable tablet ( ) aspirin (ECOTRIN) enteric coated tablet ( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min ( ) enoxaparin (LOVENOX) syringe - For	
prophylaxis  No pharmacologic VTE prophylaxis due to the following contraindication(s):  () apixaban (ELIQUIS) tablet  2.5 mg, oral, every 12 hours, Starting S+1 Indications:  () aspirin chewable tablet  () aspirin (ECOTRIN) enteric coated tablet  () enoxaparin (LOVENOX) injection (Single Response)  (Selection Required)  () enoxaparin (LOVENOX) syringe  40 mg, subcutaneous, daily at 0600, Starting S+1  () enoxaparin (LOVENOX) syringe  30 mg, subcutaneous, 2 times daily at 0600, Starting S+1  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min.  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min.  30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL)	
contraindication(s):  () apixaban (ELIQUIS) tablet  2.5 mg, oral, every 12 hours, Starting S+1 Indications:  () aspirin chewable tablet  () aspirin (ECOTRIN) enteric coated tablet  () enoxaparin (LOVENOX) injection (Single Response) (Selection Required)  () enoxaparin (LOVENOX) syringe  () enoxaparin (LOVENOX) syringe  40 mg, subcutaneous, daily at 0600, Starting S+1  () enoxaparin (LOVENOX) syringe  30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min  () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min.  () enoxaparin (LOVENOX) syringe - For  30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
( ) apixaban (ELIQUIS) tablet  2.5 mg, oral, every 12 hours, Starting S+1 Indications: ( ) aspirin chewable tablet ( ) aspirin (ECOTRIN) enteric coated tablet ( ) enoxaparin (LOVENOX) injection (Single Response) (Selection Required) ( ) enoxaparin (LOVENOX) syringe ( ) enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 ( ) enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 ( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) For Patients with CrCL LESS than 30 mL/min.	
Indications:  () aspirin chewable tablet	
( ) aspirin (ECOTRIN) enteric coated tablet 162 mg, oral, daily, Starting S+1 ( ) enoxaparin (LOVENOX) injection (Single Response)     (Selection Required) ( ) enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 ( ) enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 ( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI For Patients with CrCL LESS than 30 mL/min. ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
( ) enoxaparin (LOVENOX) injection (Single Response)     (Selection Required) ( ) enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 ( ) enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 ( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI STARTING S+1) ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI STARTING S+1)	
() enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
( ) enoxaparin (LOVENOX) syringe  30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1  ( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min  ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1  For Patients with CrCL LESS than 30 mL/min.  30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1  For Patients with CrCL LESS than 30 mL/min.  30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1  For Patients with CrCL LESS than 30 mL/min.	
Starting S+1  ( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min  ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min.  ( ) enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
Patients with CrCL LESS than 30 mL/min  ( ) enoxaparin (LOVENOX) syringe - For  7	CAL),
() enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
Patients weight between 100-139 kg and Starting S+1	CAL),
CrCl GREATER than 30 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.	
( ) enoxaparin (LOVENOX) syringe - For 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	CAL),
Patients weight between 140 kg or Starting S+1	
GREATER and CrCl GREATER than 30 For Patients weight 140 kg or GREATER and CrCl GREATER to	han 30
mL/min mL/min	
( ) fondaparinux (ARIXTRA) injection  2.5 mg, subcutaneous, daily, Starting S+1	
If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this me	dication
Contraindicated in patients LESS than 50kg, prior to surgery/inva	
procedure, or CrCl LESS than 30 mL/min	SIVC
This patient has a history of or suspected case of Heparin-Induce	ed
Thrombocytopenia (HIT):	
( ) heparin (porcine) injection 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM	
() heparin (porcine) injection (Recommended 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM	
for patients with high risk of bleeding, e.g. Recommended for patients with high risk of bleeding, e.g. weight	LESS
weight < 50kg and age > 75yrs) than 50kg and age GREATER than 75yrs.	
( ) rivaroxaban (XARELTO) tablet for hip or 10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1	
knee arthroplasty planned during this To be Given on Post Op Day 1.	
admission Indications:	
( ) warfarin (COUMADIN) tablet oral, daily at 1700, Starting S+1 Indication:	
( ) Pharmacy consult to manage warfarin STAT, Until discontinued, Starting S Indication:	

Required)

Mechanical Prophylaxis (Single Response) (Selection

() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
DVT Risk and Prophylaxis Tool (Single Response)	URL: "\appt1.pdf"
( ) Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
( ) LOW Risk of DVT (Selection Required)	·
Low Risk Definition  Age less than 60 years and NO other VTE risk factors	ors
[] Low Risk (Single Response) (Selection Required	
() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation PACU & Post-op
() MODERATE Risk of DVT - Surgical (Selection Req	uired)
contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflamma stroke, rheumatologic disease, sickle cell disease, I Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	ation, dehydration, varicose veins, cancer, sepsis, obesity, previous eg swelling, ulcers, venous stasis and nephrotic syndrome
[] Moderate Risk (Selection Required) [] Moderate risk of VTE	Routine, Once, PACU & Post-op
[] Moderate Risk Pharmacological Prophylaxis - Su	
Patient (Single Response) (Selection Required)  ( ) Contraindications exist for pharmacologic prophylaxis "And" Linked Panel	
BUT order Sequential compression device  [ ] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
Contraindications exist for pharmacologic proph AND mechanical prophylaxis	nylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[ ] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op

( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
( ) patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
( ) patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
) Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

MODERATE Risk of DVT - Non-Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate risk of VTE	Routine, Once, PACU & Post-op
Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Select Required)	tion
) Contraindications exist for pharmacologic prop Order Sequential compression device	ohylaxis - "And" Linked Panel
[ ] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[ ] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

AND mechanical prophylaxis

[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Respo	onse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
( ) patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
( ) patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
	oral, daily at 1700, PACU & Post-op Indication:
	STAT, Until discontinued, Starting S Indication:
HIGH Risk of DVT - Surgical (Selection Required)	

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) (Selection Required)	
( ) Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	sponse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min

( ) patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
( ) patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
( ) Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Se Required)	lection
( ) Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
HIGH Risk of DVT - Non-Surgical (Selection Requ	uired)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Non-Su Patient (Single Response) (Selection Required)	urgical
( ) Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	onse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
( ) patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
( ) patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min

() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 ml./min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
( ) Toridaparinux (ARIXTRA) injection	If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
<ul> <li>( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
( ) Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Sele Required)	ection
( ) Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
( ) HIGH Risk of DVT - Surgical (Hip/Knee) (Selection Required)	

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Hip of (Arthroplasty) Surgical Patient (Single Respon (Selection Required)	
( ) Contraindications exist for pharmacologic prophylaxis	Routine, Once  No pharmacologic VTE prophylaxis due to the following contraindication(s):
( ) apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
( ) aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
<ul><li>( ) enoxaparin (LOVENOX) injection (Single Res (Selection Required)</li></ul>	sponse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
( ) enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min.

( ) enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30
	mL/min.
() enoxaparin (LOVENOX) syringe - For	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL),
Patients weight between 140 kg or	Starting S+1
GREATER and CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
( ) Torradpartitus (Attorra y Injection	If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min
	This patient has a history of or suspected case of Heparin-Induced
	Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LESS
weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
( ) rivaroxaban (XARELTO) tablet for hip or	10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1
knee arthroplasty planned during this	To be Given on Post Op Day 1.
admission	Indications:
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1
	Indication:
( ) Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
(COUMADIN)	Indication:
[] Mechanical Prophylaxis (Single Response) (Se Required)	election
( ) Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s)
	PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
abs	
aboratory	
Type and screen	Once, PACU & Post-op
Hemoglobin and hematocrit	Once
	In Recovery room., PACU & Post-op
Basic metabolic panel	Once, PACU & Post-op
CBC with platelet and differential	Once, PACU & Post-op
Partial thromboplastin time	Once, PACU & Post-op
Prothrombin time with INR	Once, PACU & Post-op
Calcium level	Once, PACU & Post-op
Magnesium level	Once, PACU & Post-op
Phosphorus level	Once, PACU & Post-op
Blood gas, arterial	Once, PACU & Post-op
Urinalysis screen and microscopy, with reflex to c	
1,7,	Specimen Source: Urine
	Specimen Site:
	PACU & Post-op
aha AM	
abs - AM	

CBC with platelet and differential

Basic metabolic panel

[X] Partial thromboplastin time

[] Prothrombin time with INR

Labs - AM Daily x 3

[] Hemoglobin

AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op

AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op

AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op

AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op

AM draw repeats For 3 Occurrences, PACU & Post-op

lmaging	
СТ	
[] CT Cervical Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op
[] CT Thoracic Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op
X-ray	
[] Chest 1 Vw Portable	Routine, 1 time imaging For 1 , PACU & Post-op
[] Chest 1 Vw Portable in AM [] XR Spine Scoliosis 2-3 Views	Routine, 1 time imaging, Starting S+1 For 1, PACU & Post-op Routine, 1 time imaging For 1
[] AR Spirie Scollosis 2-3 Views	Please add 32 millimeter image calibration necklace to the field of view., PACU & Post-op
[] Cervical Spine 2 Or 3 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
Respiratory	
Respiratory	
[X] Oxygen therapy - Simple face mask	Routine, Continuous
English and tage in the contract of the contra	Device: Simple Face Mask
	Rate in liters per minute: 6 Lpm
	Rate in tenths of a liter per minute:
	O2 %:
	Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Immediate post-op period
	Device 2:
	Device 3:
	Wean prn., PACU & Post-op
[] Incentive spirometry	Routine, Once, PACU & Post-op
[] Mechanical ventilation	Routine, PACU & Post-op
	Mechanical Ventilation:
	Vent Management Strategies:
	Vent Management Strategies: Vent Management Strategies:
	Vent Management Strategies:
Consults	
For Physician Consult orders use sidebar	
Ancillary Consults	
[] Consult to Case Management	Consult Reason: PACU & Post-op
[] Consult to Social Work	Reason for Consult:
[] Concar to Coolar Work	PACU & Post-op
[X] Consult PT eval and treat	Reasons for referral to Physical Therapy (mark all applicable):
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation( if
	values are very abnormal):
	Weight Bearing Status: PACU & Post-op
[] Consult PT wound care	Special Instructions:
[] Consult Fit would cale	Location of Wound?
	PACU & Post-op
[X] Consult OT eval and treat	Reason for referral to Occupational Therapy (mark all that
	apply):
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation( if values are very abnormal):
	Weight Bearing Status:
	PACU & Post-op
	·

[] Consult to Nutrition Services	Reason For Consult? Purpose/Topic: PACU & Post-op
[] Consult to Spiritual Care	Reason for consult? PACU & Post-op
[] Consult to Speech Language Pathology	Routine, Once Reason for consult: PACU & Post-op
[] Consult to Wound Ostomy Care nurse	Reason for consult: Reason for consult: Reason for consult: Reason for consult: Consult for NPWT: Reason for consult: PACU & Post-op
[] Consult to Respiratory Therapy	Reason for Consult? PACU & Post-op
Physician Consults	
[] Consult Intensive Care	Reason for Consult? Patient/Clinical information communicated? Patient/clinical information communicated? PACU & Post-op
[] Consult Physical Medicine Rehab	Reason for Consult? Patient/Clinical information communicated? Patient/clinical information communicated? PACU & Post-op